{
    "2021-06-02": [
        [
            {
                "time": "2023-10-01",
                "original_text": "Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma",
                "features": {
                    "keywords": [
                        "Kymriah",
                        "pivotal trial",
                        "strong response rates",
                        "remarkable safety profile",
                        "follicular lymphoma"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients",
                "features": {
                    "keywords": [
                        "Kisqali",
                        "longest median overall survival",
                        "postmenopausal HR+/HER2-",
                        "metastatic breast cancer"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Novartis's Late-stage Study On Cosentyx Hits Primary Endpoint Goal In Juvenile Idiopathic Arthritis",
                "features": {
                    "keywords": [
                        "Cosentyx",
                        "Late-stage Study",
                        "Primary Endpoint Goal",
                        "Juvenile Idiopathic Arthritis"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Novartis's Cosentyx Wins FDA Approval For Psoriasis In Pediatric Patients",
                "features": {
                    "keywords": [
                        "Cosentyx",
                        "FDA Approval",
                        "Psoriasis",
                        "Pediatric Patients"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Novartis presents positive Phase III results from JUNIPERA study supporting Cosentyx® as a potential treatment in a JIA population at EULAR 2021",
                "features": {
                    "keywords": [
                        "Cosentyx",
                        "Phase III results",
                        "JUNIPERA study",
                        "JIA population",
                        "EULAR 2021"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}